Innovative start up developing monoclonal antibodies in cancer and inflammatory diseases MImAbs is an innovative start-up specialized in immunotherapy. Our goal is to develop monoclonal antibodies in cancer and inflammatory diseases for third parties (academics, pharmacuetical companies, biotechnologies, etc.) Anticorps monoclonaux, Immuno-pharmacologie, Génération et bioproduction d'anticorps, and Génération d'immunoconjugués

113 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

High-Capacity Gene Therapy Vector Platform to Address Prevalent Diseases Now part of Pacira Biosciences. GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium. biotechnology, gene …

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

576 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Precision Protein Antibiotics Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

143 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Affirma Biotech develops new products to overcome the challenge of Multi Drug Resistant and Chronic Infections Affirma Biotech is a start-up company specialized in the discovery and development of new anti-infective drugs via immunomodulation.

437 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Modulating T-regulatory cells to balance immunity Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

184 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Exceptional Human Antibody Discovery Technology Trianni, Inc. is a biotech company specializing in human antibody discovery platform technology. We offer the leading in vivo platform enabling efficient discovery of fully-human monoclonal antibodies. The Trianni Mouse offers biologic drug discoverers a best-in-class solution for the isolation of therapeutic antibody candidates. Benefits over older conventional mouse immunization + humanization approaches include superior lead panels with respect to potency and diversity along with speed to the clinic and lower operating costs. We aim to make Trianni’s premium technology available to any Pharma or Biotech company engaged in antibody discovery by offering flexible licenses …

46 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Immune Biosolutions is a clinical-stage biotechnology company specializing in the discovery and engineering of avian and human antibodies for therapeutic applications. Utilizing cutting-edge technologies, we develop custom immunotherapeutic agents. Our discovery platform efficiently targets complex proteins and generate powerful, specific, and innovative antibodies. Additionally, our antibody production capability allows us to advance our own discovery programs in cancer and autoimmune diseases into the early phases of clinical development. Anticorps, Custom antibody development, Antibody, Développement sur mesure de génération d'anticorps, IgY, Chicken, Poulet, ELISA, Therapeutic Antibodies, Recombinant Antibodies, Humanized Antibodies, GPCRs, and Oncology

91 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Patient-derived organoids AI driven target discovery Gradiant Bioconvergence (GBCC) is a pioneer in the development of patient-derived cancer organoids (PDOs) on a global scale. We have established Asia’s largest PDO repository, comprising over 800 models from patients with lung, gastric, colorectal, pancreatic, and ovarian cancers, all characterized using next-generation sequencing. In parallel, we are advancing co-culture systems that integrate autologous immune cells and cancer-associated fibroblasts with our PDOs. Leveraging our comprehensive genomic, transcriptomic and drug response datasets, we are identifying and validating novel drug-resistant oncology targets through our AI-driven discovery engine and CRISPR-enabled PDO platform. Beyond oncology, GBCC is also …

89 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The company is led by a highly experienced team of biopharmaceutical executives with deep discovery, development, and commercialization expertise. The company is advancing a potential best-in-class thymic stromal lymphopoietin (TSLP) monoclonal antibody into phase 2 development and creating novel, long-acting bispecific programs for immunological diseases.

76 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A new generation of vaccines based on fusions of recombinant proteins A new generation of vaccines within animal health We develop vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care, with a very good safety profile. Veterinary, Vaccines, Animal Health, Biotech, Recombinant Vaccines, Veterinary Products, Microbiology, Wholesale, and Research and Development

112 similar entities Type: Startup Activities: manufacturing healthtech deeptech Technologies: Synthetic Biology

Enabling next generation medicines. A comprehensive platform and product suite for advanced therapeutics. Gene therapy, Synthetic Biology, Genome Engineering, and Functional Genomics

169 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

LinKinVax aims at creating a universal, safe, enduring, vaccines platform against multiple pathogens. We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology.

158 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

402 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Adding Quality Years of Life We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

205 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

A Member of the Roche Group Poseida was acquired by Roche in early 2025 and is now part of the Roche Group. Poseida is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral DNA Delivery System, Cas-CLOVERTM Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Genome Engineering, CAR-T cells, Gene Therapy, Gene Editing, Cell Therapy, Adoptive Cell Therapy, Multiple Myeloma, Prostate Cancer, Transposon, Non-viral, Biotechnology, Immunotherapy, Regenerative …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A scalable in-vivo genetic medicine platform At Immitra Bio, we are pioneering a novel genetic medicine platform. Our innovative approach enables precise, durable, and safe gene modifications within blood stem cells, laying the foundation for scalable, curative in-vivo therapies.

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting CCN signaling to treat fibrosis Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

166 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

TG is a biopharmaceutical company focused on the development of novel treatments for B-cell diseases. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS). Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering immune interventions to treat chronic disease AstriVax Therapeutics is a European based, clinical-stage biopharmaceutical company, founded in 2022, that is pioneering immune interventions to treat chronic disease. The company has two prototype prophylactic assets in clinical phase and is developing its therapeutic assets to treat chronic HBV and clear high-risk HPV. AstriVax has a novel DNA-launched viral vector immunotherapy platform, Launch-iT, that is designed to create an inherent adjuvant effect to the target antigens, eliciting durable polyfunctional CD8+ and CD4+ T cell responses and robust humoral immunity. Through Launch-iT, the company has the potential to develop best-in-class immunotherapy treatments.

85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Phialogics state of the art platform transforms native proteins into powerful therapeutics. Phialogics is developing a pipeline of bi-functional, bi-specific and multi-specific molecules to treat autoimmune diseases. Our unique First-in-Class immunomodulatory approach has a proof of concept in several translational in vivo models as well as in patient-derived materials ex vivo.

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations. Clinical Grade Cell Therapy, Cancer Immonotherapy, Regenerative Medicine, and Stratified Medicine

205 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing drug delivery HHC medical is a health tech startup developing a platform technology for targeted and non-invasive drug delivery via wireless electroporation. Drug Delivery, Genetic therapies, and Enabling life-altering therapies

408 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Pioneering CAR Macrophage Immunotherapy to Target Solid Tumors Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA.

39 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Platelet-derived Regenerative Therapy for CNS Disorders InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.

214 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. medical device development, medical device distribution, Logistics, Procurement, Distribution, IOTH, Innovation, T-Cells, and immunology

130 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Peptide Chemistry company for design, synthesis, stability studies and chemical optimisation (SAR studies)- CIR agrement PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc...

374 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Better technology for better health LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. In addition to our proprietary research, we also develop vaccines together with GSK. vaccines, research & development, biotechnology, and antimicrobial resistance

145 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Mastering the microbiome, transforming lives® EnteroBiotix is a leading microbiome therapeutics platform company that is focussed on transforming the standard of care for patients battling debilitating diseases and infections linked to disruptions to structure and function of the gut microbiome.

198 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Focused on the development of precisely targeted, controlled & highly active T cell therapies for cancer Autolus is a CAR T cell therapy company. We are applying our extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing therapies to patients with cancer and autoimmune diseases.

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

435 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

New therapeutic targets based on arsenic trioxide (As2O3) Founded in 2010, MEDSENIC is a biopharmaceutical start-up that aims to exploit the new possibilities offered by the therapeutic use of arsenic trioxide (As2O3) and thereby provide a treatment for patients with autoimmune diseases. santé, biotechnologies, bioparma, biopharmaceutical, biotech, health, biotechnology, autoimmune diseases, and maladies auto-immunes

347 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

BioNTech Innovative Manufacturing Services (IMFS) is a subsidary of BioNTech SE. We are specialized in the development and production of innovative products (viral vectors, cells and ivt mRNA). Based on extensive expertise in scientific, technical and regulatory prerequisites, we develop and manufacture your products in a safe and cost-efficient way in our state-of-the-art GMP facilities. We offer contract services for retroviral vector manufacturing for clinical supply. The company has more than 500 experienced and highly skilled employees and is always looking for motivated people! See also www.biontech-imfs.de Cell therapy, GMP manufacturing, Gene Therapy, RNA manufacturing, Retroviral vector manufacturing, Contract Manufacturing, …

115 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Let's Build Better Cells Together We invest in our partners early on, working side by side in optimizing their processes to derisk their path to the clinic faster. Our ExPERTTM platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATxTM, STxTM, GTxTM and VLx TM; a portfolio of proprietary related processing assemblies or disposables; and software protocols, …

315 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Crafting next generation of small molecule anti-parasitic drugs by harnessing comparative structural data At ASTRA Therapeutics, we are redefining parasite drug development by leveraging the specificity of ParabulinsTM. Our mission is clear: to lead the fight against parasitic diseases with precision-engineered solutions.

505 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD) Biopharma, Oncology, Precision Medicine, Small Molecules, Targeted Therapy, Biotech, Cancer Therapy, Transcription Factors, Autoimmune Disorders, and Inflammatory Disorders

150 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Swedish biotech company exploring reprogramming as the next leap forward in cancer immunotherapy Asgard Therapeutics is a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy. The company builds on ground-breaking and proprietary reprogramming technologies to develop gene therapy products designed to set in motion efficient and personalized immune responses. Backed by top investors, Asgard Therapeutics aims to establish a pipeline of off-the shelf cancer immunotherapies that trigger personalized anti-cancer immune responses for the benefit of cancer patients in need. Cell Reprogramming, Cancer Immunotherapy, and Dendritic cells

144 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug

176 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Solution for biologics Clean Cells is a GMP-licensed Contract Development and Manufacturing Organization providing R&D, production and quality control testing services to the biopharmaceutical industry. Our two-part site located in Western France holds an innovative process development platform, BSL2 and BSL3 GMP manufacturing laboratories and analytical areas to develop bespoke assays and perform GMP testing. Clean Cells is part of the Clean Biologics group and benefits from the additional experience of sister company Naobios, a CDMO with considerable experience in the development and manufacture of virus-based products. biosafety testing, Cell Banking and Storage, Viral Clearance, Potency Assay, R&D Contract, Training, …

83 similar entities Type: SMB Activities: biotech Technologies: Synthetic Biology

Develop human organ models with true physiological complexity We are specialized in the production and development of human, immunocompetent Organ-on-Chip technology for in vitro disease and infection modelling. Organ-on-Chip, Human Cell Biology, Infection, Infectious disease, Toxicity profiling, Immune Cell Interactions, Inflammatory Diseases, Antibody recycling, and Uptake / Transport studies

125 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing

427 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

185 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules

549 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Valora Therapeutics Inc. (Valora) is a pre-clinical stage biopharmaceutical company based in San Diego, California, USA, pioneering a new biologic platform invented by Nobel Laureate Dr. Carolyn Bertozzi (Stanford). Our proprietary platform technology enables the engineering of chimeric antibodies to unlock new mechanisms of immune signaling and activity, paving the way for transformative therapies in oncology, immune diseases, and beyond.

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible.

258 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of gene and cell therapies. Precigen: Advancing Medicine with PrecisionTM Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

coIMMUNE is a privately held, clinical stage immune-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a novel CAR therapy that promises enhanced efficacy with greatly reduced toxicity.

106 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Discovery of innovative therapeutic antibodies for human and animal health MabGenesis is a biopharmaceutical startup that delivers first-in-class and best-in-class therapeutic monoclonal antibodies using technologies established by 30+ years of academic research. By using the innovative technology platform, high-quality phage display antibody libraries (MOURA Libraries) and efficient antibody isolation technology (IMPACT), MabGenesis makes it possible to isolate 100% species-specific monoclonal antibodies rapidly and efficiently. MabGenesis is a private company headquartered in Yokohama, Japan. For more information, visit https://mabgenesis.com/en Biotechnology, Antibody, Monoclonal antibody, VHH, membrane protein, Canine, Feline, GPCR, Autoimmune diseases, Cancer, Inflammatory diseases, Phage display antibodies, and Antibodydiscovery

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Creating Tomorrow's Immunotherapies NXI therapeutics focuses on the research and development of a new generation of selective immunosuppressive drugs for autoimmune diseases and transplantations - with objectives of high efficacy, good safety without adverse effects as seen with conventional immunosuppressants.

188 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Exploiting a proprietary tech platform to develop biomolecular tools for therapeutic & synthetic biology applications PartitionBio Exploiting a novel proprietary technology platform to develop biomolecular tools for the use in therapeutic and synthetic biology applications. contact@partitionbio.co.uk

326 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Leading the Next Frontier of Cell Therapy Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle. cell therapy and autoimmune disease

48 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our next-generation genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. We believe the future of cell therapy is off-the-shelf, and we are advancing our pipeline of off-the-shelf, or allogeneic, cell therapies from our CAR-T cell therapy platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Next-generation CRISPR genome editing, allogeneic CAR-T cell therapies, oncology, and …

83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing a new class of ADCs based on NMT inhibition to treat cancer We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

224 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing technologies for the biopharma industry to allow them to treat the root causes of diseases and disorders. Based in Lausanne, Switzerland, NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines for the improved production of viral vectors used in gene therapies. gene therapy, cell therapy, next-generation sequencing, NGS, rAAV, viral vectors, biologics, stable cell lines, Genomic Integration, stem cell, bioinformatics, capsid optimization, HEK293, gene expression, ATMPs, genomic, epigenetic, transcriptomic, mammalian cell lines, and human cell lines

286 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Living Immunotherapies Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary exclusive product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com Immunotherapies and T Cell receptors TCR

56 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Immunic is a biotechnology company developing small molecule therapies for chronic inflammatory and autoimmune diseases Immunic (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Privacy Policy: https://imux.com/privacy-policy/

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

163 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

265 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

Utilizing unique protein superglue technology to develop vaccines against infectious disease and cancer worldwide SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases. SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. The company’s current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for this year. Vaccine Development

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis

410 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Delivering the next generation gene therapies AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors Gene Therapy, Ophthalmology, and Rare diseases

338 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR). Monoclonal Antibody , Infectious Disease, Cell line Engineering, Inhalation therapy

103 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology